A Study Evaluating the Effect of Omnaris Nasal Spray 200 Mcg QD and Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 Mcg BID and QVAR Inhalation Aerosol 40 Mcg BID vs Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma and Allergic Rhinitis

Trial Profile

A Study Evaluating the Effect of Omnaris Nasal Spray 200 Mcg QD and Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 Mcg BID and QVAR Inhalation Aerosol 40 Mcg BID vs Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma and Allergic Rhinitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Ciclesonide (Primary) ; Ciclesonide (Primary) ; Beclometasone; Beclometasone
  • Indications Allergic rhinitis; Asthma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Mar 2016 Status changed from recruiting to completed according to results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 06 Feb 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top